Global Blood Therapeutics (GBT) is a biotechnology company founded in 2011 and based in the United States. Most recently, the company received a significant $300.00M Post-IPO Debt investment on 15 December 2021.
GBT's dedication to addressing the unmet needs of individuals living with sickle cell disease has been underscored by its recent acquisition by Pfizer. This acquisition presents an opportunity for GBT to further its mission as part of a global pharmaceutical leader, leveraging Pfizer's resources and expertise to expand its impact.
As a result of this acquisition, followers of GBT are encouraged to transition to following Pfizer, where they can expect to find new content and updates related to GBT's ongoing work in the field.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $300.00M | - | 15 Dec 2021 | |
| Post-IPO Equity | $200.00M | - | 26 Jun 2019 | |
| Post-IPO Equity | $125.00M | - | 01 Aug 2017 | |
| Post-IPO Equity | $143.80M | 1 | Cowen Investment Management | 21 Feb 2017 |
| Post-IPO Equity | $112.00M | - | 20 Jun 2016 |
We care about your data, and we'd love to use cookies make your experience better.
